Objective To investigate the changes and clinical significance of serum urokinase type plasminogen activator receptor(suPAR), soluble myeloid cells trigger receptor 1 (sTREM-1), tumor necrosis factor-ɑ(TNF-ɑ), interleukin-6(IL-6) in patients with community-acquired pneumonia(CAP). Methods A total of 100 CAP patients in our hospital from Apr 2018 to Sep 2020 were selected, 50 cases of CAP were in severe group and 50 cases of CAP were non-severe group, while 50 healthy people who had physical examination in our hospital during the same period were selected as control group. The serum levels of suPAR, sTREM-1, TNF-α and IL-6 in each group were detected by enzyme-linked immunosorbent assay, the severity of CAP patients were evaluated by Pneumonia Severity Score(PSI), Acute Physiology and Chronic Health Assessment Ⅱ(APACHE Ⅱ) scoring system. Results suPAR, sTREM-1, TNF-α, IL-6 were higher in severe group than those in non-severe group, and the above indexes in non-severe group were higher than those in control group(P<0.05). PSI, APACHEⅡ scores in severe group were higher than those in non-severe group(all P<0.01). Correlation analysis showed that suPAR, sTREM-1, TNF-α, IL-6 levels were positively correlated with PSI score and APACHE Ⅱ score (r=0.867, 0.858, 0.723, 0.853, 0.846, 0.711, 0.821; all P<0.01). By prognosis outcome, the severe group was subdivided into death group (18 cases) and survival group (32 cases), and the levels of suPAR, sTREM-1 and IL-6 in death group were higher than those in survival group (all P<0.01). Logistic regression analysis showed that suPAR, sTREM-1, IL-6 levels were dependent risks for severe CAP (P<0.05). ROC curve analysis showed that AUCs of suPAR, sTREM-1, and IL-6 for the detection of severe CAP were 0.876, 0.831, 0.780, 0.852, respectively (P<0.01). Conclusion suPAR,sTREM-1, IL-6 in CAP patients are significantly increased, and they were positively correlated with the severity and prognosis of the disease, and could be used as reference indicators for the examination of severe CAP.